3020-81-3

Basic information

• Product Name: Butyramidine hydrochloride
• Synonyms: BUTYRAMIDINE HYDROCHLORIDE;butyramidinium chloride;butanimidamide hydrochloride;BUTANIMIDAMIDE HCL;2,2'',6,6''-TETRACHLORO DIPHENYL DISULFIDE;butyrimidamide hydrochloride;2-(Dimethylamino)ethaneimine;N,N-Dimethyl-2-iminoethylamine
• CAS NO: 3020-81-3
• Molecular Formula: C₄H₁₀N₂*ClH
• Molecular Weight: 122.6
• Mol File: 3020-81-3.mol
• Article Data: 6

Chemical Properties

• Melting Point: 107-108 °C
• Boiling Point: 117.2 °C at 760 mmHg
• Flash Point: 24.7 °C
• Appearance: white powder-like solid
• Density: 1.59g/cm³
• Vapor Pressure: 6.12E-06mmHg at 25°C
• Refractive Index: 1.707
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: Methanol (Slightly), Water (Slightly)
• CAS DataBase Reference: Butyramidine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Butyramidine hydrochloride(3020-81-3)
• EPA Substance Registry System: Butyramidine hydrochloride(3020-81-3)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 3020-81-3(Hazardous Substances Data)

Usage

Description

Butyramidine hydrochloride is an organic compound that serves as a valuable reagent in the field of organic synthesis, particularly for the preparation of new derivatives of pyrimidines.

Uses

Used in Organic Synthesis:
Butyramidine hydrochloride is used as a reagent for the preparation of new derivatives of pyrimidines, which are important in the development of various chemical compounds and pharmaceuticals. Its role in organic synthesis is crucial for creating novel pyrimidine-based molecules with potential applications in different industries.

InChI:InChI=1/C12H6Cl4S2/c13-7-3-1-4-8(14)11(7)17-18-12-9(15)5-2-6-10(12)16/h1-6H

Upstream product

• 2208-08-4 ethyl butyrimidate hydrochloride 
• 109-74-0 propyl cyanide 

Downstream Products

• 476363-40-3 5,7-dihydro-2-propyl-6H-pyrimido[5,4-d][1]benzazepine-6-one 
• 68282-39-3 2-n-Propyl-4-hydroxymethylimidazole 
• 91272-25-2 2-propyl-5,6,7,8,9,10-hexahydrocycloocta[d]pyrimidin-4(3H)-one 
• 23902-01-4 2-propyl-5,6,7,8-tetrahydroquinazolin-4(3H)-one 
• 23902-03-6 2-propyl-6,7,8,9-tetrahydro-3H-cyclohepta[d]pyrimidin-4(5H)-one 
• 101596-22-9 3-phenyl-5-propyl-4H-1,2,4-triazole 
• 144689-94-1 diethyl 2-(n-propyl)-1H-imidazole-4,5-dicarboxylate 
• 98489-74-8 5-methyl-2-propyl-1H-pyrimidine-4,6-dione 
• 114426-12-9 5-ethyl-2-propyl-1H-pyrimidine-4,6-dione 
• 98432-22-5 6-amino-2-propyl-3H-pyrimidin-4-one 
• 99167-54-1 2,5-dipropyl-1H-pyrimidine-4,6-dione 
• 100531-39-3 5-hexyl-2-propyl-1H-pyrimidine-4,6-dione 
• 3603-18-7 2-propyl-1H-pyrimidine-4,6-dione 
• 1430808-91-5 6-propylindolo[1,2-c]quinazoline 

Relevant articles and documents

Discovery of the bifunctional modulator of angiotensin II type 1 receptor (AT1R) and PPARγ derived from the AT1R antagonist, Fimasartan

Inspired by the well-known PPARγ partial agonism of angiotensin II type 1 receptor (AT1R) antagonists exemplified by an antihypertensive drug, Telmisartan, efforts to identify compounds with the dual activities have been pursued in order to control the two major metabolic disorders, hypertension and hyperglycemia simultaneously. Lead compound 18 derived from the AT1R antagonist, Fimasartan, has successfully presented the possibility to control the medical conditions by a single molecule.

Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists

The discovery, in vitro and in vivo studies of the highly potent AT1 antagonist 12a (BR-A-657, Fimasartan) are presented. A series of pyrimidin-4(3H)-one derivatives as losartan analogue were synthesized and evaluated for a novel class of AT1 receptor antagonists. Among them, 12a containing thioamido moiety displayed both high in vitro functional antagonism and binding affinity [IC50 = 0.42 and 0.13 nM, respectively] and inhibited strongly in vivo AngII-induced pressor response in pithed rats with an ED50 of 0.018 mg/kg. Moreover, in vivo evaluation in furosemide-treated rat and conscious renal hypertensive rat models and the pharmacokinetic study showed that 12a is a highly potent and orally active AT1 selective antagonist having stronger in vivo potency than losartan.

Oxindolylquinazoline derivatives as angiogenesis inhibitors

The invention relates to compounds of formula (I) and salts thereof as further defined herein, wherein ring Z is a 6-membered heterocyclic ring containing 1 to 3 nitrogen atoms, and the use of such compounds and salts to inhibit the effects of VEGF and FGF, and in the treatment of a number of disease states including cancer and rheumatoid arthritis.